HIV/AIDS Topics HIV Reservoir Found in Blood Progenitor Cells in Bone Marrow
- Details
- Category: Search for a Cure
- Published on Friday, 12 March 2010 13:15
- Written by Liz Highleyman
HIV can hide in the bone marrow inside hematopoietic progenitor stem cells, even in people with long-term undetectable plasma viral load, according to study results reported in the March 7, 2010 online edition of Nature Medicine. When the cells are forced to differentiate into different types of blood cells, the viral genome becomes active and begins producing new viral particles. The ramifications of this finding are not yet clear, but will certainly have implications for the growing effort to accomplish HIV eradication.
CROI 2010: LEDGF/p75 Integrase Inhibitors and Capsid Assembly Inhibitors Offer New Approaches for Blocking HIV Replication
- Details
- Category: HIV Treatment
- Published on Tuesday, 02 March 2010 12:57
- Written by Liz Highleyman
While the drug development pipeline is not as full as it has been in recent years, researchers continue to work on new approaches to antiretroviral therapy. Two such novel approaches -- LEDGF integrase inhibitors and capsid assembly inhibitors -- were described in oral presentations at the recent 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010) last month in San Francisco.
CROI 2010: Investigational Drug TBR-652 Demonstrates Dual Activity against CCR5 and CCR2 Co-receptors
- Details
- Category: Experimental HIV Drugs
- Published on Tuesday, 23 February 2010 12:57
- Written by Liz Highleyman
Tobira Therapeutics' investigational CCR5 antagonist TBR-652 was shown to have potent anti-HIV activity and it appeared safe and well-tolerated in its first small trial in people with HIV, researchers reported last week at the 17th Conference on Retroviruses & Opportunistic Infections (CROI 2010) in San Francisco. The drug also blocked CCR2, suggesting it might be useful as an anti-inflammatory agent.
CROI 2010: ACTG 5202 Shows Abacavir/lamivudine and Tenofovir/emtricitabine Provide Similar HIV Suppression at Low Viral Loads
- Details
- Category: HIV Treatment
- Published on Tuesday, 02 March 2010 12:57
- Written by Liz Highleyman
Two widely used components of first-line combination antiretroviral therapy (ART) -- abacavir/lamivudine (Epzicom) and tenofovir/emtricitabine (Truvada) -- suppress HIV viral load about equally well when combined with either the NNRTI efavirenz (Sustiva) or the ritonavir-boosted protease inhibitor atazanavir (Reyataz) in people with low baseline viral loads, according to final results from the ACTG 5202 trial reported at the 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010) last month in San Francisco.
CROI 2010: Treatment Intensification with Maraviroc (Selzentry) Did Not Raise CD4 Cell Counts in Small Study
- Details
- Category: HIV Treatment
- Published on Tuesday, 23 February 2010 12:57
- Written by Liz Highleyman
Adding the CCR5 antagonist maraviroc (Selzentry) to an antiretroviral regimen that is already fully suppressing HIV viral load did not produce larger CD4 cell gains among people whose immune recovery was stalled, according to a small study presented at the 17th Conference on Retroviruses & Opportunistic Infections (CROI 2010) last week in San Francisco. Maraviroc did, however, appear to dampen immune activation.
FDA Announces Preliminary Data Suggesting Heart Risk with Saquinavir (Invirase) plus Ritonavir (Norvir)
- Details
- Category: Drug Advisories & Warnings
- Published on Friday, 26 February 2010 13:15
- Written by FDA
On February 23, the U.S. Food and Drug Administration (FDA) announced an ongoing safety review looking at the combination of the older protease inhibitor saquinavir (Invirase) plus a boosting dose of ritonavir (Norvir). Preliminary data -- arising out of an FDA request that protease inhibitor manufacturers perform a thorough electrocardiogram study -- suggest that this combination may alter the electrical rhythm of the heart, leading to symptoms such as shortness of breath and potentially cardiac arrest. The FDA recommends that this combination should not be used by people taking other heart-altering drugs, but emphasized that patients should not stop taking these drugs without consulting a medical provider.
CROI 2010: Once-daily Boosted Darunavir (Prezista) Works as Well as Twice-daily for Treatment-experienced Patients
- Details
- Category: HIV Treatment
- Published on Tuesday, 16 February 2010 00:00
- Written by Liz Highleyman
Taking ritonavir-boosted darunavir (Prezista) once instead of twice per day leads to equally good virological suppression in previously treated individuals, accoriding to a presentation at the 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010) last week in San Francisco. The once-daily regimen was associated wit fewer side effects and did not lead to development of drug-resistance mutations.
More Articles...
- Antiretroviral Therapy Does Not Improve HIV-associated Pulmonary Arterial Hypertension, but High CD4 Cell Count Reduces Mortality
- Atripla Label Information Updated to Reflect New Efficacy, Safety, and Resistance Data in Treatment-experienced Patients
- Experimental CCR5 Antagonist Vicriviroc Appears Safe and Well Tolerated in HIV/HCV Coinfected Patients
- Antiretroviral Therapy Reduces Overall Mortality, but Effects Differ According to HIV Risk Group
- Leakage of Gut Bacteria May Continue in People with Low-level HIV Despite Antiretroviral Therapy
Web Design and Development by